Neupogen and Tisagenlecleucel

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using filgrastim during or too soon after tisagenlecleucel infusion may alter the effects of both treatments. Medications like filgrastim should generally not be given for at least 3 weeks after tisagenlecleucel treatment or until resolution of cytokine release syndrome (CRS), which is a potentially life-threatening condition that may occur following treatment with tisagenlecleucel and often requires hospitalization. Signs and symptoms of CRS include dizziness; lightheadedness; low blood pressure; high fever; difficulty breathing; chills or shaking chills; severe nausea, vomiting, and diarrhea; and severe muscle and joint pain. Heart, liver, or kidney function may also be affected in some patients with CRS. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

ADJUST DOSING INTERVAL: Concurrent administration of tisagenlecleucel and hematopoietic growth factors may interfere with the pharmacologic effects of both, since the former targets B-cell lymphoblasts and the latter stimulate myeloid cell proliferation.

MANAGEMENT: Hematopoietic growth factors, particularly granulocyte-macrophage colony-stimulating factor (GM-CSF), are not recommended during the first 3 weeks following tisagenlecleucel administration or until cytokine release syndrome (CRS) has resolved.

Neupogen

Generic Name: filgrastim

Brand name: Neupogen, Neupogen SingleJect, Nivestym, Zarxio

Synonyms: n.a.

What is Neupogen?

Tisagenlecleucel

Generic Name: tisagenlecleucel

Brand name: Kymriah

Synonyms: n.a.

What is Tisagenlecleucel?